These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1499005)

  • 1. Pharmacogenetics of tricyclic and novel antidepressants: recent developments.
    Brøsen K; Gram LF; Sindrup S; Skjelbo E; Nielsen KK
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():80A-81A. PubMed ID: 1499005
    [No Abstract]   [Full Text] [Related]  

  • 2. [Role of pharmacogenetics in psychopharmacotherapy].
    Gram LF
    Encephale; 1991; 17 Spec No 1():123-5. PubMed ID: 1864259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics and drug metabolism of newer antidepressant agents.
    DeVane CL
    J Clin Psychiatry; 1994 Dec; 55 Suppl():38-45; discussion 46-7. PubMed ID: 7814357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.
    Rogers JF; Nafziger AN; Bertino JS
    Am J Med; 2002 Dec; 113(9):746-50. PubMed ID: 12517365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19.
    de Leon J
    J Clin Psychopharmacol; 2007 Jun; 27(3):241-5. PubMed ID: 17502769
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacogenetics: Part II.
    Gibaldi M
    Ann Pharmacother; 1992 Feb; 26(2):255-61. PubMed ID: 1554942
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetically variable metabolism of antidepressants and neuroleptic drugs in man.
    Dahl ML; Bertilsson L
    Pharmacogenetics; 1993 Apr; 3(2):61-70. PubMed ID: 8100166
    [No Abstract]   [Full Text] [Related]  

  • 9. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.
    Harvey AT; Preskorn SH
    Arch Gen Psychiatry; 1995 Sep; 52(9):783-5. PubMed ID: 7654130
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.
    Thuerauf N; Lunkenheimer J
    Eur Arch Psychiatry Clin Neurosci; 2006 Aug; 256(5):287-93. PubMed ID: 16783493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.
    Olesen OV; Linnet K
    Drug Metab Dispos; 1997 Jun; 25(6):740-4. PubMed ID: 9193876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.
    Kirchheiner J; Brøsen K; Dahl ML; Gram LF; Kasper S; Roots I; Sjöqvist F; Spina E; Brockmöller J
    Acta Psychiatr Scand; 2001 Sep; 104(3):173-92. PubMed ID: 11531654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.
    LLerena A; Herraíz AG; Cobaleda J; Johansson I; Dahl ML
    Clin Pharmacol Ther; 1993 Dec; 54(6):606-11. PubMed ID: 7903915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.
    Yokono A; Morita S; Someya T; Hirokane G; Okawa M; Shimoda K
    J Clin Psychopharmacol; 2001 Dec; 21(6):549-55. PubMed ID: 11763000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
    Koyama E; Tanaka T; Chiba K; Kawakatsu S; Morinobu S; Totsuka S; Ishizaki T
    J Clin Psychopharmacol; 1996 Aug; 16(4):286-93. PubMed ID: 8835703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics to prevent maniac affective switching with treatment for bipolar disorder: CYP2D6.
    Sánchez-Martín A; Sánchez-Iglesias S; García-Berrocal B; Lorenzo C; Gaedigk A; Isidoro-García M
    Pharmacogenomics; 2016 Aug; 17(12):1291-3. PubMed ID: 27469479
    [No Abstract]   [Full Text] [Related]  

  • 17. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Practical issues related to medication selection.
    Smoller JW
    CNS Spectr; 2006 Mar; 11(3 Suppl 3):5-7. PubMed ID: 17760223
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
    Hicks JK; Sangkuhl K; Swen JJ; Ellingrod VL; Müller DJ; Shimoda K; Bishop JR; Kharasch ED; Skaar TC; Gaedigk A; Dunnenberger HM; Klein TE; Caudle KE; Stingl JC
    Clin Pharmacol Ther; 2017 Jul; 102(1):37-44. PubMed ID: 27997040
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients.
    Shimoda K; Someya T; Yokono A; Morita S; Hirokane G; Takahashi S; Okawa M
    J Clin Psychopharmacol; 2002 Aug; 22(4):371-8. PubMed ID: 12172336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
    Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1989; 36(6):537-47. PubMed ID: 2570698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.